The difference in GBE activity for the homozygous and compound heterozygous patients does not seem to make a difference functionally. But clinical assessments need to confirm this point.
Does the 10-percentage point lower GBE activity in compound heterozygous APBD patients translate into worse symptoms?
April 13th, 2018|